Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis

Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):343-51. doi: 10.1161/CIRCOUTCOMES.111.000032. Epub 2013 May 7.

Abstract

Background: Acute rheumatic fever and subsequent rheumatic heart disease remain significant in developing countries. We describe a cost-effective analysis of 7 strategies for the primary prevention of acute rheumatic fever and rheumatic heart disease in children presenting with pharyngitis in urban primary care clinics in South Africa.

Methods and results: We used a Markov model to assess the cost-effectiveness of treatment with intramuscular penicillin using each of the following strategies: (1) empirical (treat all); (2) positive throat culture (culture all); (3) clinical decision rule (CDR) score ≥2 (CDR 2+); (4) CDR score ≥3 (CDR 3+); (5) treating those with a CDR score ≥2 plus those with CDR score <2 and positive cultures (CDR 2+, culture CDR negatives); (6) treating those with a CDR score ≥3 plus those with CDR score <3 and positive cultures (CDR 3+, culture CDR negatives); and (7) treat none. The strategies ranked in order from lowest cost were treat all ($11.19 per child), CDR 2+ ($11.20); the CDR 3+ ($13.00); CDR 2+, culture CDR negatives ($16.42); CDR 3+, culture CDR negatives ($23.89); and culture all ($27.21). The CDR 2+ is the preferred strategy at less than $150/quality-adjusted life year compared with the treat all strategy. A strategy of culturing all children compared with the CDR 2+ strategy costs more than $125 000/quality-adjusted life year gained.

Conclusions: Treating all children presenting with pharyngitis in urban primary care clinics in South Africa with intramuscular penicillin is the least costly. A strategy of using a clinical decision rule without culturing is overall the preferred strategy. A strategy of culturing all children may be prohibitively expensive.

Keywords: cost-benefit analysis; prevention; rheumatic heart disease.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / economics*
  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis
  • Delivery of Health Care / economics
  • Developing Countries / economics*
  • Drug Costs*
  • Humans
  • Markov Chains
  • Models, Economic
  • Penicillins / adverse effects
  • Penicillins / economics*
  • Penicillins / therapeutic use*
  • Pharyngitis / diagnosis
  • Pharyngitis / drug therapy*
  • Pharyngitis / economics*
  • Pharyngitis / epidemiology
  • Pharyngitis / microbiology
  • Prevalence
  • Primary Prevention / economics*
  • Quality-Adjusted Life Years
  • Rheumatic Fever / diagnosis
  • Rheumatic Fever / economics*
  • Rheumatic Fever / epidemiology
  • Rheumatic Fever / microbiology
  • Rheumatic Fever / prevention & control*
  • Rheumatic Heart Disease / diagnosis
  • Rheumatic Heart Disease / economics*
  • Rheumatic Heart Disease / epidemiology
  • Rheumatic Heart Disease / microbiology
  • Rheumatic Heart Disease / prevention & control*
  • South Africa / epidemiology
  • Treatment Outcome
  • Urban Health Services / economics

Substances

  • Anti-Bacterial Agents
  • Penicillins